Author:
Croteau David,Mikkelsen Tom
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Reference30 articles.
1. Cairncross G, Macdonald D, Ludwin S, et al.: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994, 12:2013–2021. This was the first major paper to recognize the chemotherapy sensitivity of anaplastic oligodendroglioma, which led to the identification of specific molecular genetic markers.
2. Pathology and genetics of tumours of the nervous system. Edited by Kleihues P, Cavanee WK. Lyon, France: IARC Press, 2000.
3. Gilbert MR, Supko J, Grossman SA, et al.: Dose requirements, pharmacology and activity of CPT-11 in patients with recurrent high-grade glioma. A NABTT CNS consortium trial. 36th American Society for Clinical Oncology Annual Meeting, New Orleans, LA: May 20–23, 2000. Proc Am Soc Clin Oncol 2000, 19:161a [abstract 622].
4. Grossman S, Hochberg F, Fisher JD, et al.: Increased 9-aminocamptothecin requirements in patients on anticonvulsants. Cancer Chemother Pharmacol 1998, 42:118–126. This was the first paper that documented the interaction of anticonvulsants and cytotoxic agents, which have changed how phase I clinical trials are conducted in malignant gliomas.
5. Scott JN, Rewscale NB, Brasher PMA, et al.: Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 1999, 46:183–188. The prognostic factors in brain tumor patients and their importance in interpreting clinical efficacy trials are highlighted in this paper.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献